Classification
Compound class	Synthetic organic

IUPAC Name

(E)-N-[(1R)-1-[3,5-difluoro-4-(methanesulfonamido)phenyl]ethyl]-3-[2-propyl-6-(trifluoromethyl)pyridin-3-yl]prop-2-enamide

International Nonproprietary Names
INN number	INN
10566	asivatrep

Synonyms

Example 230 [US7858621] | PAC-14028

Database Links
CAS Registry No.	1005168-10-4 (source: WHO INN record)
ChEMBL Ligand	CHEMBL3707398
GtoPdb PubChem SID	340590251
PubChem CID	56649347
Search Google for chemical match using the InChIKey	UKGJZDSUJSPAJL-YPUOHESYSA-N
Search Google for chemicals with the same backbone	UKGJZDSUJSPAJL
Search PubMed clinical trials	asivatrep
Search PubMed titles	asivatrep
Search PubMed titles/abstracts	asivatrep
Search UniChem for chemical match using the InChIKey	UKGJZDSUJSPAJL-YPUOHESYSA-N
Search UniChem for chemicals with the same backbone	UKGJZDSUJSPAJL

Comments

Asivatrep (PAC-14028) is an antagonist of the transient receptor potential vanilloid type 1 (TRPV1) channel, developed by AmorePacific for anti-inflammatory potential in refractory dermatoses [2]. It is claimed as example 230 in patent US7858621 [1]. PAC-14028 is administered topically for skin inflammation.